#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Cancer has been a major threat to human health in recent years .
2-1	16-22	Cancer	abstract	new	coref	2-4[3_0]
2-2	23-26	has	_	_	_	_
2-3	27-31	been	_	_	_	_
2-4	32-33	a	abstract[3]	giv[3]	coref	4-13[0_3]
2-5	34-39	major	abstract[3]	giv[3]	_	_
2-6	40-46	threat	abstract[3]	giv[3]	_	_
2-7	47-49	to	abstract[3]	giv[3]	_	_
2-8	50-55	human	abstract[3]|abstract[4]	giv[3]|new[4]	_	_
2-9	56-62	health	abstract[3]|abstract[4]	giv[3]|new[4]	_	_
2-10	63-65	in	abstract[3]|abstract[4]	giv[3]|new[4]	_	_
2-11	66-72	recent	abstract[3]|abstract[4]|time[5]	giv[3]|new[4]|new[5]	coref	3-2[6_5]
2-12	73-78	years	abstract[3]|abstract[4]|time[5]	giv[3]|new[4]|new[5]	_	_
2-13	79-80	.	_	_	_	_

#Text=In the past forty years , even though great efforts have been made , there is still much to be done before a safe therapy is achieved .
3-1	81-83	In	_	_	_	_
3-2	84-87	the	time[6]	giv[6]	_	_
3-3	88-92	past	time[6]	giv[6]	_	_
3-4	93-98	forty	time[6]	giv[6]	_	_
3-5	99-104	years	time[6]	giv[6]	_	_
3-6	105-106	,	_	_	_	_
3-7	107-111	even	_	_	_	_
3-8	112-118	though	_	_	_	_
3-9	119-124	great	abstract[7]	new[7]	_	_
3-10	125-132	efforts	abstract[7]	new[7]	_	_
3-11	133-137	have	_	_	_	_
3-12	138-142	been	_	_	_	_
3-13	143-147	made	_	_	_	_
3-14	148-149	,	_	_	_	_
3-15	150-155	there	_	_	_	_
3-16	156-158	is	_	_	_	_
3-17	159-164	still	_	_	_	_
3-18	165-169	much	_	_	_	_
3-19	170-172	to	_	_	_	_
3-20	173-175	be	_	_	_	_
3-21	176-180	done	_	_	_	_
3-22	181-187	before	_	_	_	_
3-23	188-189	a	event[8]	new[8]	coref	7-7[27_8]
3-24	190-194	safe	event[8]	new[8]	_	_
3-25	195-202	therapy	event[8]	new[8]	_	_
3-26	203-205	is	_	_	_	_
3-27	206-214	achieved	_	_	_	_
3-28	215-216	.	_	_	_	_

#Text=Currently , chemotherapy and radiotherapy are still the main therapeutic methods for cancer .
4-1	217-226	Currently	_	_	_	_
4-2	227-228	,	_	_	_	_
4-3	229-241	chemotherapy	abstract	new	_	_
4-4	242-245	and	_	_	_	_
4-5	246-258	radiotherapy	abstract	new	coref	4-7[11_0]
4-6	259-262	are	_	_	_	_
4-7	263-268	still	abstract[11]	giv[11]	_	_
4-8	269-272	the	abstract[11]	giv[11]	_	_
4-9	273-277	main	abstract[11]	giv[11]	_	_
4-10	278-289	therapeutic	abstract[11]	giv[11]	_	_
4-11	290-297	methods	abstract[11]	giv[11]	_	_
4-12	298-301	for	abstract[11]	giv[11]	_	_
4-13	302-308	cancer	abstract[11]|abstract	giv[11]|giv	coref	7-17
4-14	309-310	.	_	_	_	_

#Text=However , most of the anticancer drugs have toxic side effects .
5-1	311-318	However	_	_	_	_
5-2	319-320	,	_	_	_	_
5-3	321-325	most	substance[14]	new[14]	coref	6-8[18_14]
5-4	326-328	of	substance[14]	new[14]	_	_
5-5	329-332	the	substance[14]	new[14]	_	_
5-6	333-343	anticancer	abstract|substance[14]	new|new[14]	coref	24-16
5-7	344-349	drugs	substance[14]	new[14]	_	_
5-8	350-354	have	_	_	_	_
5-9	355-360	toxic	abstract[15]	new[15]	coref	6-13[20_15]
5-10	361-365	side	abstract[15]	new[15]	_	_
5-11	366-373	effects	abstract[15]	new[15]	_	_
5-12	374-375	.	_	_	_	_

#Text=Therefore , it is critical to develop novel anticancer drugs that have no toxic side effects on other tissues or organs in vivo , and only target the lesion area .
6-1	376-385	Therefore	_	_	_	_
6-2	386-387	,	_	_	_	_
6-3	388-390	it	event	new	cata	6-3[0_17]
6-4	391-393	is	_	_	_	_
6-5	394-402	critical	_	_	_	_
6-6	403-405	to	event[17]	new[17]	_	_
6-7	406-413	develop	event[17]|abstract	new[17]|new	coref|none	16-10[104_0]|6-7[0_186]
6-8	414-419	novel	event[17]|substance[18]	new[17]|giv[18]	coref	7-3[25_18]
6-9	420-430	anticancer	event[17]|substance[18]	new[17]|giv[18]	_	_
6-10	431-436	drugs	event[17]|substance[18]	new[17]|giv[18]	_	_
6-11	437-441	that	_	_	_	_
6-12	442-446	have	_	_	_	_
6-13	447-449	no	abstract[20]	giv[20]	_	_
6-14	450-455	toxic	abstract[20]	giv[20]	_	_
6-15	456-460	side	abstract|abstract[20]	new|giv[20]	_	_
6-16	461-468	effects	abstract[20]	giv[20]	_	_
6-17	469-471	on	abstract[20]	giv[20]	_	_
6-18	472-477	other	abstract[20]|object[21]	giv[20]|new[21]	_	_
6-19	478-485	tissues	abstract[20]|object[21]	giv[20]|new[21]	_	_
6-20	486-488	or	abstract[20]	giv[20]	_	_
6-21	489-495	organs	abstract[20]|abstract[22]	giv[20]|new[22]	_	_
6-22	496-498	in	abstract[20]|abstract[22]	giv[20]|new[22]	_	_
6-23	499-503	vivo	abstract[20]|abstract[22]	giv[20]|new[22]	_	_
6-24	504-505	,	_	_	_	_
6-25	506-509	and	_	_	_	_
6-26	510-514	only	_	_	_	_
6-27	515-521	target	_	_	_	_
6-28	522-525	the	abstract[24]	new[24]	coref	19-12[128_24]
6-29	526-532	lesion	abstract|abstract[24]	new|new[24]	_	_
6-30	533-537	area	abstract[24]	new[24]	_	_
6-31	538-539	.	_	_	_	_

#Text=Compared with traditional chemotherapeutic drugs , the nano-anticancer drug therapy has potential application prospects in curing cancer diseases .
7-1	540-548	Compared	_	_	_	_
7-2	549-553	with	_	_	_	_
7-3	554-565	traditional	substance[25]	giv[25]	coref	8-7[34_25]
7-4	566-582	chemotherapeutic	substance[25]	giv[25]	_	_
7-5	583-588	drugs	substance[25]	giv[25]	_	_
7-6	589-590	,	_	_	_	_
7-7	591-594	the	event[27]	giv[27]	_	_
7-8	595-610	nano-anticancer	event[27]	giv[27]	_	_
7-9	611-615	drug	substance|event[27]	new|giv[27]	coref	26-16
7-10	616-623	therapy	event[27]	giv[27]	_	_
7-11	624-627	has	_	_	_	_
7-12	628-637	potential	abstract[29]	new[29]	_	_
7-13	638-649	application	abstract|abstract[29]	new|new[29]	coref	26-13[184_0]
7-14	650-659	prospects	abstract[29]	new[29]	_	_
7-15	660-662	in	_	_	_	_
7-16	663-669	curing	_	_	_	_
7-17	670-676	cancer	abstract|abstract[31]	giv|new[31]	coref	22-15[144_0]
7-18	677-685	diseases	abstract[31]	new[31]	_	_
7-19	686-687	.	_	_	_	_

#Text=One of the major concerns about the nano-anticancer drugs is the drug-delivery vector .
8-1	688-691	One	abstract[32]	new[32]	coref	8-11[35_32]
8-2	692-694	of	abstract[32]	new[32]	_	_
8-3	695-698	the	abstract[32]|abstract[33]	new[32]|new[33]	_	_
8-4	699-704	major	abstract[32]|abstract[33]	new[32]|new[33]	_	_
8-5	705-713	concerns	abstract[32]|abstract[33]	new[32]|new[33]	_	_
8-6	714-719	about	abstract[32]|abstract[33]	new[32]|new[33]	_	_
8-7	720-723	the	abstract[32]|abstract[33]|substance[34]	new[32]|new[33]|giv[34]	coref	12-40[72_34]
8-8	724-739	nano-anticancer	abstract[32]|abstract[33]|substance[34]	new[32]|new[33]|giv[34]	_	_
8-9	740-745	drugs	abstract[32]|abstract[33]|substance[34]	new[32]|new[33]|giv[34]	_	_
8-10	746-748	is	_	_	_	_
8-11	749-752	the	abstract[35]	giv[35]	coref	9-1[37_35]
8-12	753-766	drug-delivery	abstract[35]	giv[35]	_	_
8-13	767-773	vector	abstract[35]	giv[35]	_	_
8-14	774-775	.	_	_	_	_

#Text=The ideal delivery vector should possess such characteristics as a high drug-loading capacity , low immunogenicity , low toxicity , better shelf-life , and water solubility , and it should have the potential to be further modified .
9-1	776-779	The	abstract[37]	giv[37]	ana	9-29[0_37]
9-2	780-785	ideal	abstract[37]	giv[37]	_	_
9-3	786-794	delivery	abstract|abstract[37]	new|giv[37]	coref	11-12
9-4	795-801	vector	abstract[37]	giv[37]	_	_
9-5	802-808	should	_	_	_	_
9-6	809-816	possess	_	_	_	_
9-7	817-821	such	abstract[38]	new[38]	_	_
9-8	822-837	characteristics	abstract[38]	new[38]	_	_
9-9	838-840	as	abstract[38]	new[38]	_	_
9-10	841-842	a	abstract[38]	new[38]	_	_
9-11	843-847	high	abstract[38]	new[38]	_	_
9-12	848-860	drug-loading	abstract[38]|substance	new[38]|new	_	_
9-13	861-869	capacity	abstract[38]	new[38]	_	_
9-14	870-871	,	abstract[38]	new[38]	_	_
9-15	872-875	low	abstract[38]	new[38]	_	_
9-16	876-890	immunogenicity	abstract[38]	new[38]	_	_
9-17	891-892	,	abstract[38]	new[38]	_	_
9-18	893-896	low	abstract[38]	new[38]	_	_
9-19	897-905	toxicity	abstract[38]	new[38]	_	_
9-20	906-907	,	abstract[38]	new[38]	_	_
9-21	908-914	better	abstract[38]	new[38]	_	_
9-22	915-925	shelf-life	abstract[38]	new[38]	_	_
9-23	926-927	,	abstract[38]	new[38]	_	_
9-24	928-931	and	abstract[38]	new[38]	_	_
9-25	932-937	water	abstract[38]|substance	new[38]|new	_	_
9-26	938-948	solubility	abstract[38]	new[38]	_	_
9-27	949-950	,	_	_	_	_
9-28	951-954	and	_	_	_	_
9-29	955-957	it	abstract	giv	coref	27-35[197_0]
9-30	958-964	should	_	_	_	_
9-31	965-969	have	_	_	_	_
9-32	970-973	the	abstract[42]	new[42]	_	_
9-33	974-983	potential	abstract[42]	new[42]	_	_
9-34	984-986	to	_	_	_	_
9-35	987-989	be	_	_	_	_
9-36	990-997	further	_	_	_	_
9-37	998-1006	modified	_	_	_	_
9-38	1007-1008	.	_	_	_	_

#Text=Synthetic polymers , such as , chitosan , polyetherimide ( PEI ) , poly(lactic-co-glycolic acid ) ( PLGA ) , polyamidoamine ( PAMAM ) , and poly-l-lactic acid ( PLA ) have been widely used in gene- and drug-delivery systems .
10-1	1009-1018	Synthetic	substance[43]	new[43]	_	_
10-2	1019-1027	polymers	substance[43]	new[43]	_	_
10-3	1028-1029	,	substance[43]	new[43]	_	_
10-4	1030-1034	such	substance[43]	new[43]	_	_
10-5	1035-1037	as	substance[43]	new[43]	_	_
10-6	1038-1039	,	substance[43]	new[43]	_	_
10-7	1040-1048	chitosan	substance[43]|substance	new[43]|new	_	_
10-8	1049-1050	,	_	_	_	_
10-9	1051-1065	polyetherimide	substance	new	appos	10-14[47_0]
10-10	1066-1067	(	_	_	_	_
10-11	1068-1071	PEI	person	new	_	_
10-12	1072-1073	)	_	_	_	_
10-13	1074-1075	,	_	_	_	_
10-14	1076-1099	poly(lactic-co-glycolic	substance[47]	giv[47]	coref	10-27[50_47]
10-15	1100-1104	acid	substance[47]	giv[47]	_	_
10-16	1105-1106	)	_	_	_	_
10-17	1107-1108	(	_	_	_	_
10-18	1109-1113	PLGA	_	_	_	_
10-19	1114-1115	)	_	_	_	_
10-20	1116-1117	,	_	_	_	_
10-21	1118-1132	polyamidoamine	substance	new	appos	10-23
10-22	1133-1134	(	_	_	_	_
10-23	1135-1140	PAMAM	substance	giv	_	_
10-24	1141-1142	)	_	_	_	_
10-25	1143-1144	,	_	_	_	_
10-26	1145-1148	and	_	_	_	_
10-27	1149-1162	poly-l-lactic	substance[50]	giv[50]	_	_
10-28	1163-1167	acid	substance[50]	giv[50]	_	_
10-29	1168-1169	(	_	_	_	_
10-30	1170-1173	PLA	abstract	new	_	_
10-31	1174-1175	)	_	_	_	_
10-32	1176-1180	have	_	_	_	_
10-33	1181-1185	been	_	_	_	_
10-34	1186-1192	widely	_	_	_	_
10-35	1193-1197	used	_	_	_	_
10-36	1198-1200	in	_	_	_	_
10-37	1201-1206	gene-	abstract|abstract[53]	new|new[53]	_	_
10-38	1207-1210	and	abstract[53]	new[53]	_	_
10-39	1211-1224	drug-delivery	abstract[53]	new[53]	_	_
10-40	1225-1232	systems	abstract[53]	new[53]	_	_
10-41	1233-1234	.	_	_	_	_

#Text=However , stability of sustained-release formulations in aqueous solution , long delivery times , and low delivery efficiency are only a small part of the challenges highlighted by researchers .
11-1	1235-1242	However	_	_	_	_
11-2	1243-1244	,	_	_	_	_
11-3	1245-1254	stability	abstract[54]	new[54]	_	_
11-4	1255-1257	of	abstract[54]	new[54]	_	_
11-5	1258-1275	sustained-release	abstract[54]|substance[55]	new[54]|new[55]	_	_
11-6	1276-1288	formulations	abstract[54]|substance[55]	new[54]|new[55]	_	_
11-7	1289-1291	in	abstract[54]|substance[55]	new[54]|new[55]	_	_
11-8	1292-1299	aqueous	abstract[54]|substance[55]|substance[56]	new[54]|new[55]|new[56]	_	_
11-9	1300-1308	solution	abstract[54]|substance[55]|substance[56]	new[54]|new[55]|new[56]	_	_
11-10	1309-1310	,	abstract[54]|substance[55]	new[54]|new[55]	_	_
11-11	1311-1315	long	abstract[54]|substance[55]|time[58]	new[54]|new[55]|new[58]	_	_
11-12	1316-1324	delivery	abstract[54]|substance[55]|abstract|time[58]	new[54]|new[55]|giv|new[58]	coref	11-17
11-13	1325-1330	times	abstract[54]|substance[55]|time[58]	new[54]|new[55]|new[58]	_	_
11-14	1331-1332	,	abstract[54]|substance[55]	new[54]|new[55]	_	_
11-15	1333-1336	and	abstract[54]|substance[55]	new[54]|new[55]	_	_
11-16	1337-1340	low	abstract[54]|substance[55]|abstract[60]	new[54]|new[55]|new[60]	_	_
11-17	1341-1349	delivery	abstract[54]|substance[55]|abstract|abstract[60]	new[54]|new[55]|giv|new[60]	coref	14-12[89_0]
11-18	1350-1360	efficiency	abstract[54]|substance[55]|abstract[60]	new[54]|new[55]|new[60]	_	_
11-19	1361-1364	are	_	_	_	_
11-20	1365-1369	only	_	_	_	_
11-21	1370-1371	a	_	_	_	_
11-22	1372-1377	small	_	_	_	_
11-23	1378-1382	part	_	_	_	_
11-24	1383-1385	of	_	_	_	_
11-25	1386-1389	the	abstract[61]	new[61]	_	_
11-26	1390-1400	challenges	abstract[61]	new[61]	_	_
11-27	1401-1412	highlighted	_	_	_	_
11-28	1413-1415	by	_	_	_	_
11-29	1416-1427	researchers	person	new	_	_
11-30	1428-1429	.	_	_	_	_

#Text=Dendrigraft poly-l-lysines ( DGL ) have emerged as a new kind of synthetic polymer consisting of lysine and have been employed as drug- or gene-delivery carriers , due to their biodegradability and rich external amino groups that can encapsulate drugs by the emulsion crosslinking method or plasmid DNA through electric interactions .
12-1	1430-1441	Dendrigraft	abstract[63]	new[63]	ana	12-30[0_63]
12-2	1442-1456	poly-l-lysines	abstract[63]	new[63]	_	_
12-3	1457-1458	(	_	_	_	_
12-4	1459-1462	DGL	object	new	coref	20-10[133_0]
12-5	1463-1464	)	_	_	_	_
12-6	1465-1469	have	_	_	_	_
12-7	1470-1477	emerged	_	_	_	_
12-8	1478-1480	as	_	_	_	_
12-9	1481-1482	a	_	_	_	_
12-10	1483-1486	new	_	_	_	_
12-11	1487-1491	kind	substance[65]	new[65]	_	_
12-12	1492-1494	of	substance[65]	new[65]	_	_
12-13	1495-1504	synthetic	substance[65]	new[65]	_	_
12-14	1505-1512	polymer	substance[65]	new[65]	_	_
12-15	1513-1523	consisting	_	_	_	_
12-16	1524-1526	of	_	_	_	_
12-17	1527-1533	lysine	substance	new	_	_
12-18	1534-1537	and	_	_	_	_
12-19	1538-1542	have	_	_	_	_
12-20	1543-1547	been	_	_	_	_
12-21	1548-1556	employed	_	_	_	_
12-22	1557-1559	as	_	_	_	_
12-23	1560-1565	drug-	_	_	_	_
12-24	1566-1568	or	_	_	_	_
12-25	1569-1582	gene-delivery	abstract	new	_	_
12-26	1583-1591	carriers	_	_	_	_
12-27	1592-1593	,	_	_	_	_
12-28	1594-1597	due	_	_	_	_
12-29	1598-1600	to	_	_	_	_
12-30	1601-1606	their	abstract|person[71]	giv|new[71]	ana	13-2
12-31	1607-1623	biodegradability	substance|person[71]	new|new[71]	coref	13-2[79_0]
12-32	1624-1627	and	person[71]	new[71]	_	_
12-33	1628-1632	rich	person[71]	new[71]	_	_
12-34	1633-1641	external	person[71]	new[71]	_	_
12-35	1642-1647	amino	object|person[71]	new|new[71]	_	_
12-36	1648-1654	groups	person[71]	new[71]	_	_
12-37	1655-1659	that	_	_	_	_
12-38	1660-1663	can	_	_	_	_
12-39	1664-1675	encapsulate	_	_	_	_
12-40	1676-1681	drugs	substance[72]	giv[72]	coref	14-15[90_72]
12-41	1682-1684	by	substance[72]	giv[72]	_	_
12-42	1685-1688	the	substance[72]|abstract[75]	giv[72]|new[75]	_	_
12-43	1689-1697	emulsion	substance[72]|event|abstract[75]	giv[72]|new|new[75]	_	_
12-44	1698-1710	crosslinking	substance[72]|event|abstract[75]	giv[72]|new|new[75]	_	_
12-45	1711-1717	method	substance[72]|abstract[75]	giv[72]|new[75]	_	_
12-46	1718-1720	or	substance[72]	giv[72]	_	_
12-47	1721-1728	plasmid	substance[72]|object[76]	giv[72]|new[76]	_	_
12-48	1729-1732	DNA	substance[72]|object[76]	giv[72]|new[76]	_	_
12-49	1733-1740	through	_	_	_	_
12-50	1741-1749	electric	abstract[77]	new[77]	_	_
12-51	1750-1762	interactions	abstract[77]	new[77]	_	_
12-52	1763-1764	.	_	_	_	_

#Text=Besides their biodegradability , they can also be modified with targeting ligands and polyethylene glycol ( PEG ) , thereby rendering vectors with targeting properties and long circulation .
13-1	1765-1772	Besides	_	_	_	_
13-2	1773-1778	their	person|substance[79]	giv|giv[79]	ana	13-5
13-3	1779-1795	biodegradability	substance[79]	giv[79]	_	_
13-4	1796-1797	,	_	_	_	_
13-5	1798-1802	they	person	giv	_	_
13-6	1803-1806	can	_	_	_	_
13-7	1807-1811	also	_	_	_	_
13-8	1812-1814	be	_	_	_	_
13-9	1815-1823	modified	_	_	_	_
13-10	1824-1828	with	_	_	_	_
13-11	1829-1838	targeting	_	_	_	_
13-12	1839-1846	ligands	substance	new	_	_
13-13	1847-1850	and	_	_	_	_
13-14	1851-1863	polyethylene	substance|substance[83]	new|new[83]	_	_
13-15	1864-1870	glycol	substance[83]	new[83]	_	_
13-16	1871-1872	(	_	_	_	_
13-17	1873-1876	PEG	object	new	_	_
13-18	1877-1878	)	_	_	_	_
13-19	1879-1880	,	_	_	_	_
13-20	1881-1888	thereby	_	_	_	_
13-21	1889-1898	rendering	_	_	_	_
13-22	1899-1906	vectors	object[85]	new[85]	_	_
13-23	1907-1911	with	object[85]	new[85]	_	_
13-24	1912-1921	targeting	object[85]|abstract[86]	new[85]|new[86]	_	_
13-25	1922-1932	properties	object[85]|abstract[86]	new[85]|new[86]	_	_
13-26	1933-1936	and	object[85]	new[85]	_	_
13-27	1937-1941	long	object[85]|abstract[87]	new[85]|new[87]	_	_
13-28	1942-1953	circulation	object[85]|abstract[87]	new[85]|new[87]	_	_
13-29	1954-1955	.	_	_	_	_

#Text=As yet , there are only a few ways available for targeted delivery of anticancer drugs .
14-1	1956-1958	As	_	_	_	_
14-2	1959-1962	yet	_	_	_	_
14-3	1963-1964	,	_	_	_	_
14-4	1965-1970	there	_	_	_	_
14-5	1971-1974	are	_	_	_	_
14-6	1975-1979	only	_	_	_	_
14-7	1980-1981	a	abstract[88]	new[88]	_	_
14-8	1982-1985	few	abstract[88]	new[88]	_	_
14-9	1986-1990	ways	abstract[88]	new[88]	_	_
14-10	1991-2000	available	abstract[88]	new[88]	_	_
14-11	2001-2004	for	_	_	_	_
14-12	2005-2013	targeted	abstract[89]	giv[89]	_	_
14-13	2014-2022	delivery	abstract[89]	giv[89]	_	_
14-14	2023-2025	of	abstract[89]	giv[89]	_	_
14-15	2026-2036	anticancer	abstract[89]|substance[90]	giv[89]|giv[90]	coref	16-10[103_90]
14-16	2037-2042	drugs	abstract[89]|substance[90]	giv[89]|giv[90]	_	_
14-17	2043-2044	.	_	_	_	_

#Text=Recently , a report showed that VAR2CSA , which is exposed on the membrane of Plasmodium falciparum infected red blood cells ( iRBC ) , could bind to 90 % of tumors , which was verified by running immunohistochemistry on a tumor-tissue array .
15-1	2045-2053	Recently	_	_	_	_
15-2	2054-2055	,	_	_	_	_
15-3	2056-2057	a	abstract[91]	new[91]	_	_
15-4	2058-2064	report	abstract[91]	new[91]	_	_
15-5	2065-2071	showed	_	_	_	_
15-6	2072-2076	that	_	_	_	_
15-7	2077-2084	VAR2CSA	abstract	new	coref	16-3
15-8	2085-2086	,	_	_	_	_
15-9	2087-2092	which	_	_	_	_
15-10	2093-2095	is	_	_	_	_
15-11	2096-2103	exposed	_	_	_	_
15-12	2104-2106	on	_	_	_	_
15-13	2107-2110	the	place[93]	new[93]	_	_
15-14	2111-2119	membrane	place[93]	new[93]	_	_
15-15	2120-2122	of	place[93]	new[93]	_	_
15-16	2123-2133	Plasmodium	place[93]|substance|object[95]	new[93]|new|new[95]	_	_
15-17	2134-2144	falciparum	place[93]|object[95]	new[93]|new[95]	_	_
15-18	2145-2153	infected	place[93]|object[95]|object[96]	new[93]|new[95]|new[96]	appos	15-23[0_96]
15-19	2154-2157	red	place[93]|object[95]|object[96]	new[93]|new[95]|new[96]	_	_
15-20	2158-2163	blood	place[93]|object[95]|object[96]	new[93]|new[95]|new[96]	_	_
15-21	2164-2169	cells	place[93]|object[95]|object[96]	new[93]|new[95]|new[96]	_	_
15-22	2170-2171	(	_	_	_	_
15-23	2172-2176	iRBC	object	giv	coref	17-11
15-24	2177-2178	)	_	_	_	_
15-25	2179-2180	,	_	_	_	_
15-26	2181-2186	could	_	_	_	_
15-27	2187-2191	bind	_	_	_	_
15-28	2192-2194	to	_	_	_	_
15-29	2195-2197	90	quantity[98]	new[98]	_	_
15-30	2198-2199	%	quantity[98]	new[98]	_	_
15-31	2200-2202	of	quantity[98]	new[98]	_	_
15-32	2203-2209	tumors	quantity[98]|object	new[98]|new	_	_
15-33	2210-2211	,	_	_	_	_
15-34	2212-2217	which	_	_	_	_
15-35	2218-2221	was	_	_	_	_
15-36	2222-2230	verified	_	_	_	_
15-37	2231-2233	by	_	_	_	_
15-38	2234-2241	running	_	_	_	_
15-39	2242-2262	immunohistochemistry	abstract	new	_	_
15-40	2263-2265	on	_	_	_	_
15-41	2266-2267	a	object[101]	new[101]	_	_
15-42	2268-2280	tumor-tissue	object[101]	new[101]	_	_
15-43	2281-2286	array	object[101]	new[101]	_	_
15-44	2287-2288	.	_	_	_	_

#Text=Therefore , VAR2CSA is becoming an attractive target for anticancer drugs ’ development .
16-1	2289-2298	Therefore	_	_	_	_
16-2	2299-2300	,	_	_	_	_
16-3	2301-2308	VAR2CSA	substance	giv	coref	17-33
16-4	2309-2311	is	_	_	_	_
16-5	2312-2320	becoming	_	_	_	_
16-6	2321-2323	an	_	_	_	_
16-7	2324-2334	attractive	_	_	_	_
16-8	2335-2341	target	_	_	_	_
16-9	2342-2345	for	_	_	_	_
16-10	2346-2356	anticancer	substance[103]|abstract[104]	giv[103]|new[104]	coref	26-16[186_104]
16-11	2357-2362	drugs	substance[103]|abstract[104]	giv[103]|new[104]	_	_
16-12	2363-2364	’	substance[103]|abstract[104]	giv[103]|new[104]	_	_
16-13	2365-2376	development	abstract[104]	new[104]	_	_
16-14	2377-2378	.	_	_	_	_

#Text=P. falciparum infection during pregnancy results in the sequestration of iRBC in the placenta by adhering to a distinct type of chondroitin sulfate A ( CSA ) exclusively expressed on trophoblast via VAR2CSA .
17-1	2379-2381	P.	event[105]	new[105]	_	_
17-2	2382-2392	falciparum	event[105]	new[105]	_	_
17-3	2393-2402	infection	event[105]	new[105]	_	_
17-4	2403-2409	during	event[105]	new[105]	_	_
17-5	2410-2419	pregnancy	event[105]|event|abstract[107]	new[105]|new|new[107]	_	_
17-6	2420-2427	results	event[105]|abstract[107]	new[105]|new[107]	_	_
17-7	2428-2430	in	event[105]|abstract[107]	new[105]|new[107]	_	_
17-8	2431-2434	the	event[105]|abstract[107]|abstract[108]	new[105]|new[107]|new[108]	_	_
17-9	2435-2448	sequestration	event[105]|abstract[107]|abstract[108]	new[105]|new[107]|new[108]	_	_
17-10	2449-2451	of	event[105]|abstract[107]|abstract[108]	new[105]|new[107]|new[108]	_	_
17-11	2452-2456	iRBC	event[105]|abstract[107]|abstract[108]|substance	new[105]|new[107]|new[108]|giv	coref	22-42[155_0]
17-12	2457-2459	in	event[105]|abstract[107]|abstract[108]	new[105]|new[107]|new[108]	_	_
17-13	2460-2463	the	event[105]|abstract[107]|abstract[108]|place[110]	new[105]|new[107]|new[108]|new[110]	coref	19-5[0_110]
17-14	2464-2472	placenta	event[105]|abstract[107]|abstract[108]|place[110]	new[105]|new[107]|new[108]|new[110]	_	_
17-15	2473-2475	by	_	_	_	_
17-16	2476-2484	adhering	_	_	_	_
17-17	2485-2487	to	_	_	_	_
17-18	2488-2489	a	quantity[111]	new[111]	_	_
17-19	2490-2498	distinct	quantity[111]	new[111]	_	_
17-20	2499-2503	type	quantity[111]	new[111]	_	_
17-21	2504-2506	of	quantity[111]	new[111]	_	_
17-22	2507-2518	chondroitin	quantity[111]|person	new[111]|new	_	_
17-23	2519-2526	sulfate	quantity[111]|person	new[111]|new	_	_
17-24	2527-2528	A	quantity[111]	new[111]	_	_
17-25	2529-2530	(	_	_	_	_
17-26	2531-2534	CSA	place	new	coref	18-12
17-27	2535-2536	)	_	_	_	_
17-28	2537-2548	exclusively	_	_	_	_
17-29	2549-2558	expressed	_	_	_	_
17-30	2559-2561	on	_	_	_	_
17-31	2562-2573	trophoblast	place[115]	new[115]	_	_
17-32	2574-2577	via	place[115]	new[115]	_	_
17-33	2578-2585	VAR2CSA	place[115]|object	new[115]|giv	coref	18-5
17-34	2586-2587	.	_	_	_	_

#Text=Short continuous regions of VAR2CSA with affinity for multiple types of CSA were defined .
18-1	2588-2593	Short	place[117]	new[117]	_	_
18-2	2594-2604	continuous	place[117]	new[117]	_	_
18-3	2605-2612	regions	place[117]	new[117]	_	_
18-4	2613-2615	of	place[117]	new[117]	_	_
18-5	2616-2623	VAR2CSA	place[117]|abstract	new[117]|giv	coref	19-13
18-6	2624-2628	with	place[117]	new[117]	_	_
18-7	2629-2637	affinity	place[117]|abstract[119]	new[117]|new[119]	_	_
18-8	2638-2641	for	place[117]|abstract[119]	new[117]|new[119]	_	_
18-9	2642-2650	multiple	place[117]|abstract[119]|abstract[120]	new[117]|new[119]|new[120]	_	_
18-10	2651-2656	types	place[117]|abstract[119]|abstract[120]	new[117]|new[119]|new[120]	_	_
18-11	2657-2659	of	place[117]|abstract[119]|abstract[120]	new[117]|new[119]|new[120]	_	_
18-12	2660-2663	CSA	place[117]|abstract[119]|abstract[120]|abstract	new[117]|new[119]|new[120]|giv	_	_
18-13	2664-2668	were	_	_	_	_
18-14	2669-2676	defined	_	_	_	_
18-15	2677-2678	.	_	_	_	_

#Text=A 28 amino acids placenta CSA-binding peptide ( plCSA-BP ) from the VAR2CSA region was recently tested as a guide peptide for targeted delivery of doxorubicin to choriocarcinoma .
19-1	2679-2680	A	person[122]|abstract[125]	new[122]|new[125]	_	_
19-2	2681-2683	28	person[122]|abstract[125]	new[122]|new[125]	_	_
19-3	2684-2689	amino	person[122]|abstract[125]	new[122]|new[125]	_	_
19-4	2690-2695	acids	person[122]|abstract[125]	new[122]|new[125]	_	_
19-5	2696-2704	placenta	place|abstract[125]	giv|new[125]	_	_
19-6	2705-2716	CSA-binding	abstract|abstract[125]	new|new[125]	_	_
19-7	2717-2724	peptide	abstract[125]	new[125]	_	_
19-8	2725-2726	(	_	_	_	_
19-9	2727-2735	plCSA-BP	object	new	coref	27-27
19-10	2736-2737	)	_	_	_	_
19-11	2738-2742	from	_	_	_	_
19-12	2743-2746	the	abstract[128]	giv[128]	_	_
19-13	2747-2754	VAR2CSA	place|abstract[128]	giv|giv[128]	_	_
19-14	2755-2761	region	abstract[128]	giv[128]	_	_
19-15	2762-2765	was	_	_	_	_
19-16	2766-2774	recently	_	_	_	_
19-17	2775-2781	tested	_	_	_	_
19-18	2782-2784	as	_	_	_	_
19-19	2785-2786	a	_	_	_	_
19-20	2787-2792	guide	_	_	_	_
19-21	2793-2800	peptide	_	_	_	_
19-22	2801-2804	for	_	_	_	_
19-23	2805-2813	targeted	abstract[129]	new[129]	coref	27-13[0_129]
19-24	2814-2822	delivery	abstract[129]	new[129]	_	_
19-25	2823-2825	of	abstract[129]	new[129]	_	_
19-26	2826-2837	doxorubicin	abstract[129]|object	new[129]|new	_	_
19-27	2838-2840	to	abstract[129]	new[129]	_	_
19-28	2841-2856	choriocarcinoma	abstract[129]|abstract	new[129]|new	ana	20-4
19-29	2857-2858	.	_	_	_	_

#Text=However , whether it could be used to modify the DGL and its bioactivity after the modification was not evaluated .
20-1	2859-2866	However	_	_	_	_
20-2	2867-2868	,	_	_	_	_
20-3	2869-2876	whether	_	_	_	_
20-4	2877-2879	it	abstract	giv	ana	20-13
20-5	2880-2885	could	_	_	_	_
20-6	2886-2888	be	_	_	_	_
20-7	2889-2893	used	_	_	_	_
20-8	2894-2896	to	_	_	_	_
20-9	2897-2903	modify	_	_	_	_
20-10	2904-2907	the	object[133]	giv[133]	coref	27-36[0_133]
20-11	2908-2911	DGL	object[133]	giv[133]	_	_
20-12	2912-2915	and	_	_	_	_
20-13	2916-2919	its	abstract|abstract[135]	giv|new[135]	coref	23-12
20-14	2920-2931	bioactivity	abstract[135]	new[135]	_	_
20-15	2932-2937	after	_	_	_	_
20-16	2938-2941	the	event[136]	new[136]	_	_
20-17	2942-2954	modification	event[136]	new[136]	_	_
20-18	2955-2958	was	_	_	_	_
20-19	2959-2962	not	_	_	_	_
20-20	2963-2972	evaluated	_	_	_	_
20-21	2973-2974	.	_	_	_	_

#Text=The immunosuppressive , antimalarial , and pro-cytotoxic bacterial prodigiosin was recently described as a potent antimetastatic and anticancer agent .
21-1	2975-2978	The	substance[138]	new[138]	ana	22-1[0_138]
21-2	2979-2996	immunosuppressive	substance[138]	new[138]	_	_
21-3	2997-2998	,	substance[138]	new[138]	_	_
21-4	2999-3011	antimalarial	substance[138]	new[138]	_	_
21-5	3012-3013	,	substance[138]	new[138]	_	_
21-6	3014-3017	and	substance[138]	new[138]	_	_
21-7	3018-3031	pro-cytotoxic	substance[138]	new[138]	_	_
21-8	3032-3041	bacterial	substance|substance[138]	new|new[138]	_	_
21-9	3042-3053	prodigiosin	substance[138]	new[138]	_	_
21-10	3054-3057	was	_	_	_	_
21-11	3058-3066	recently	_	_	_	_
21-12	3067-3076	described	_	_	_	_
21-13	3077-3079	as	_	_	_	_
21-14	3080-3081	a	_	_	_	_
21-15	3082-3088	potent	_	_	_	_
21-16	3089-3103	antimetastatic	_	_	_	_
21-17	3104-3107	and	_	_	_	_
21-18	3108-3118	anticancer	_	_	_	_
21-19	3119-3124	agent	_	_	_	_
21-20	3125-3126	.	_	_	_	_

#Text=It can induce apoptosis in a wide range of cancer cell lines , including hematopoietic cancer , breast cancer , gastric cancer , colon cancer , lung cancer , and rat hepatocellular carcinoma cell lines , with no marked toxicity in nonmalignant cells .
22-1	3127-3129	It	substance	giv	coref	23-3
22-2	3130-3133	can	_	_	_	_
22-3	3134-3140	induce	_	_	_	_
22-4	3141-3150	apoptosis	abstract[140]	new[140]	coref	24-6[160_140]
22-5	3151-3153	in	abstract[140]	new[140]	_	_
22-6	3154-3155	a	abstract[140]|abstract[141]	new[140]|new[141]	_	_
22-7	3156-3160	wide	abstract[140]|abstract[141]	new[140]|new[141]	_	_
22-8	3161-3166	range	abstract[140]|abstract[141]	new[140]|new[141]	_	_
22-9	3167-3169	of	abstract[140]|abstract[141]	new[140]|new[141]	_	_
22-10	3170-3176	cancer	abstract[140]|abstract[141]|object[143]	new[140]|new[141]|new[143]	_	_
22-11	3177-3181	cell	abstract[140]|abstract[141]|place|object[143]	new[140]|new[141]|new|new[143]	coref	22-34
22-12	3182-3187	lines	abstract[140]|abstract[141]|object[143]	new[140]|new[141]|new[143]	_	_
22-13	3188-3189	,	abstract[140]|abstract[141]	new[140]|new[141]	_	_
22-14	3190-3199	including	abstract[140]|abstract[141]	new[140]|new[141]	_	_
22-15	3200-3213	hematopoietic	abstract[140]|abstract[141]|abstract[144]	new[140]|new[141]|giv[144]	coref	22-18[145_144]
22-16	3214-3220	cancer	abstract[140]|abstract[141]|abstract[144]	new[140]|new[141]|giv[144]	_	_
22-17	3221-3222	,	abstract[140]|abstract[141]	new[140]|new[141]	_	_
22-18	3223-3229	breast	abstract[140]|abstract[141]|abstract[145]	new[140]|new[141]|giv[145]	coref	22-21[147_145]
22-19	3230-3236	cancer	abstract[140]|abstract[141]|abstract[145]	new[140]|new[141]|giv[145]	_	_
22-20	3237-3238	,	abstract[140]|abstract[141]	new[140]|new[141]	_	_
22-21	3239-3246	gastric	abstract[140]|abstract[141]|abstract|abstract[147]	new[140]|new[141]|new|giv[147]	coref	22-24[148_147]
22-22	3247-3253	cancer	abstract[140]|abstract[141]|abstract[147]	new[140]|new[141]|giv[147]	_	_
22-23	3254-3255	,	abstract[140]|abstract[141]	new[140]|new[141]	_	_
22-24	3256-3261	colon	abstract[140]|abstract[141]|abstract[148]	new[140]|new[141]|giv[148]	coref	22-27[149_148]
22-25	3262-3268	cancer	abstract[140]|abstract[141]|abstract[148]	new[140]|new[141]|giv[148]	_	_
22-26	3269-3270	,	abstract[140]|abstract[141]	new[140]|new[141]	_	_
22-27	3271-3275	lung	abstract[140]|abstract[141]|abstract[149]	new[140]|new[141]|giv[149]	coref	30-30[0_149]
22-28	3276-3282	cancer	abstract[140]|abstract[141]|abstract[149]	new[140]|new[141]|giv[149]	_	_
22-29	3283-3284	,	abstract[140]|abstract[141]	new[140]|new[141]	_	_
22-30	3285-3288	and	abstract[140]|abstract[141]	new[140]|new[141]	_	_
22-31	3289-3292	rat	abstract[140]|abstract[141]|object[153]	new[140]|new[141]|new[153]	_	_
22-32	3293-3307	hepatocellular	abstract[140]|abstract[141]|abstract|object[153]	new[140]|new[141]|new|new[153]	_	_
22-33	3308-3317	carcinoma	abstract[140]|abstract[141]|abstract|object[153]	new[140]|new[141]|new|new[153]	_	_
22-34	3318-3322	cell	abstract[140]|abstract[141]|place|object[153]	new[140]|new[141]|giv|new[153]	coref	28-23
22-35	3323-3328	lines	abstract[140]|abstract[141]|object[153]	new[140]|new[141]|new[153]	_	_
22-36	3329-3330	,	abstract[140]|abstract[141]|object[153]	new[140]|new[141]|new[153]	_	_
22-37	3331-3335	with	abstract[140]|abstract[141]|object[153]	new[140]|new[141]|new[153]	_	_
22-38	3336-3338	no	abstract[140]|abstract[141]|object[153]|abstract[154]	new[140]|new[141]|new[153]|new[154]	_	_
22-39	3339-3345	marked	abstract[140]|abstract[141]|object[153]|abstract[154]	new[140]|new[141]|new[153]|new[154]	_	_
22-40	3346-3354	toxicity	abstract[140]|abstract[141]|object[153]|abstract[154]	new[140]|new[141]|new[153]|new[154]	_	_
22-41	3355-3357	in	abstract[140]|abstract[141]|object[153]|abstract[154]	new[140]|new[141]|new[153]|new[154]	_	_
22-42	3358-3370	nonmalignant	abstract[140]|abstract[141]|object[153]|abstract[154]|object[155]	new[140]|new[141]|new[153]|new[154]|giv[155]	coref	24-8[162_155]
22-43	3371-3376	cells	abstract[140]|abstract[141]|object[153]|abstract[154]|object[155]	new[140]|new[141]|new[153]|new[154]|giv[155]	_	_
22-44	3377-3378	.	_	_	_	_

#Text=However , prodigiosin has not been reported for the treatment of choriocarcinoma yet .
23-1	3379-3386	However	_	_	_	_
23-2	3387-3388	,	_	_	_	_
23-3	3389-3400	prodigiosin	substance	giv	ana	24-1
23-4	3401-3404	has	_	_	_	_
23-5	3405-3408	not	_	_	_	_
23-6	3409-3413	been	_	_	_	_
23-7	3414-3422	reported	_	_	_	_
23-8	3423-3426	for	_	_	_	_
23-9	3427-3430	the	abstract[157]	new[157]	_	_
23-10	3431-3440	treatment	abstract[157]	new[157]	_	_
23-11	3441-3443	of	abstract[157]	new[157]	_	_
23-12	3444-3459	choriocarcinoma	abstract[157]|abstract	new[157]|giv	coref	28-22
23-13	3460-3463	yet	_	_	_	_
23-14	3464-3465	.	_	_	_	_

#Text=It is selective in promoting apoptosis of malignant tumor cells , rendering prodigiosin a promising anticancer agent .
24-1	3466-3468	It	substance	giv	coref	24-13
24-2	3469-3471	is	_	_	_	_
24-3	3472-3481	selective	_	_	_	_
24-4	3482-3484	in	_	_	_	_
24-5	3485-3494	promoting	_	_	_	_
24-6	3495-3504	apoptosis	abstract[160]	giv[160]	_	_
24-7	3505-3507	of	abstract[160]	giv[160]	_	_
24-8	3508-3517	malignant	abstract[160]|object[162]	giv[160]|giv[162]	_	_
24-9	3518-3523	tumor	abstract[160]|abstract|object[162]	giv[160]|new|giv[162]	coref	28-30
24-10	3524-3529	cells	abstract[160]|object[162]	giv[160]|giv[162]	_	_
24-11	3530-3531	,	_	_	_	_
24-12	3532-3541	rendering	_	_	_	_
24-13	3542-3553	prodigiosin	substance	giv	coref	25-5
24-14	3554-3555	a	person[165]	new[165]	_	_
24-15	3556-3565	promising	person[165]	new[165]	_	_
24-16	3566-3576	anticancer	abstract|person[165]	giv|new[165]	_	_
24-17	3577-3582	agent	person[165]	new[165]	_	_
24-18	3583-3584	.	_	_	_	_

#Text=The antitumor mechanism of prodigiosin is still unclear , especially in regard to newly acquired prodigiosin produced by a small number of microorganisms , including Serratia marcescens and other bacteria , such as Streptomyces griseoviridis , Serratia spp. , Zooshikellarubidus , Vibrio sp . , Actinomycetes , and Hahella chejuensis .
25-1	3585-3588	The	abstract[166]	new[166]	_	_
25-2	3589-3598	antitumor	abstract[166]	new[166]	_	_
25-3	3599-3608	mechanism	abstract[166]	new[166]	_	_
25-4	3609-3611	of	abstract[166]	new[166]	_	_
25-5	3612-3623	prodigiosin	abstract[166]|substance	new[166]|giv	coref	25-14[169_0]
25-6	3624-3626	is	_	_	_	_
25-7	3627-3632	still	_	_	_	_
25-8	3633-3640	unclear	_	_	_	_
25-9	3641-3642	,	_	_	_	_
25-10	3643-3653	especially	abstract[168]	new[168]	_	_
25-11	3654-3656	in	abstract[168]	new[168]	_	_
25-12	3657-3663	regard	abstract[168]	new[168]	_	_
25-13	3664-3666	to	abstract[168]	new[168]	_	_
25-14	3667-3672	newly	abstract[168]|substance[169]	new[168]|giv[169]	coref	26-6[183_169]
25-15	3673-3681	acquired	abstract[168]|substance[169]	new[168]|giv[169]	_	_
25-16	3682-3693	prodigiosin	abstract[168]|substance[169]	new[168]|giv[169]	_	_
25-17	3694-3702	produced	_	_	_	_
25-18	3703-3705	by	_	_	_	_
25-19	3706-3707	a	abstract[170]	new[170]	_	_
25-20	3708-3713	small	abstract[170]	new[170]	_	_
25-21	3714-3720	number	abstract[170]	new[170]	_	_
25-22	3721-3723	of	abstract[170]	new[170]	_	_
25-23	3724-3738	microorganisms	abstract[170]|abstract	new[170]|new	_	_
25-24	3739-3740	,	abstract[170]	new[170]	_	_
25-25	3741-3750	including	abstract[170]	new[170]	_	_
25-26	3751-3759	Serratia	abstract[170]|place[172]	new[170]|new[172]	_	_
25-27	3760-3770	marcescens	abstract[170]|place[172]	new[170]|new[172]	_	_
25-28	3771-3774	and	abstract[170]	new[170]	_	_
25-29	3775-3780	other	abstract[170]|animal[173]	new[170]|new[173]	_	_
25-30	3781-3789	bacteria	abstract[170]|animal[173]	new[170]|new[173]	_	_
25-31	3790-3791	,	abstract[170]|animal[173]	new[170]|new[173]	_	_
25-32	3792-3796	such	abstract[170]|animal[173]	new[170]|new[173]	_	_
25-33	3797-3799	as	abstract[170]|animal[173]	new[170]|new[173]	_	_
25-34	3800-3812	Streptomyces	abstract[170]|animal[173]|abstract	new[170]|new[173]|new	_	_
25-35	3813-3826	griseoviridis	abstract[170]|animal[173]	new[170]|new[173]	_	_
25-36	3827-3828	,	abstract[170]|animal[173]	new[170]|new[173]	_	_
25-37	3829-3837	Serratia	abstract[170]|animal[173]	new[170]|new[173]	_	_
25-38	3838-3842	spp.	abstract[170]|animal[173]	new[170]|new[173]	_	_
25-39	3843-3844	,	abstract[170]|animal[173]	new[170]|new[173]	_	_
25-40	3845-3863	Zooshikellarubidus	abstract[170]|animal[173]|animal	new[170]|new[173]|new	_	_
25-41	3864-3865	,	abstract[170]|animal[173]	new[170]|new[173]	_	_
25-42	3866-3872	Vibrio	abstract[170]|animal[173]|person|plant[177]	new[170]|new[173]|new|new[177]	_	_
25-43	3873-3875	sp	abstract[170]|animal[173]|plant[177]	new[170]|new[173]|new[177]	_	_
25-44	3876-3877	.	abstract[170]|animal[173]	new[170]|new[173]	_	_
25-45	3878-3879	,	abstract[170]|animal[173]	new[170]|new[173]	_	_
25-46	3880-3893	Actinomycetes	abstract[170]|animal[173]|animal	new[170]|new[173]|new	_	_
25-47	3894-3895	,	abstract[170]|animal[173]	new[170]|new[173]	_	_
25-48	3896-3899	and	abstract[170]|animal[173]	new[170]|new[173]	_	_
25-49	3900-3907	Hahella	abstract[170]|animal[173]|substance	new[170]|new[173]|new	_	_
25-50	3908-3918	chejuensis	abstract[170]|animal[173]	new[170]|new[173]	_	_
25-51	3919-3920	.	_	_	_	_

#Text=Research on the mechanism of bacterial origin prodigiosin is very important for clinical application and drug development .
26-1	3921-3929	Research	abstract[180]	new[180]	_	_
26-2	3930-3932	on	abstract[180]	new[180]	_	_
26-3	3933-3936	the	abstract[180]|abstract[181]	new[180]|new[181]	_	_
26-4	3937-3946	mechanism	abstract[180]|abstract[181]	new[180]|new[181]	_	_
26-5	3947-3949	of	abstract[180]|abstract[181]	new[180]|new[181]	_	_
26-6	3950-3959	bacterial	abstract[180]|abstract[181]|substance[183]	new[180]|new[181]|giv[183]	coref	27-22[0_183]
26-7	3960-3966	origin	abstract[180]|abstract[181]|abstract|substance[183]	new[180]|new[181]|new|giv[183]	_	_
26-8	3967-3978	prodigiosin	abstract[180]|abstract[181]|substance[183]	new[180]|new[181]|giv[183]	_	_
26-9	3979-3981	is	_	_	_	_
26-10	3982-3986	very	_	_	_	_
26-11	3987-3996	important	_	_	_	_
26-12	3997-4000	for	_	_	_	_
26-13	4001-4009	clinical	abstract[184]	giv[184]	ana	28-14[0_184]
26-14	4010-4021	application	abstract[184]	giv[184]	_	_
26-15	4022-4025	and	_	_	_	_
26-16	4026-4030	drug	substance|abstract[186]	giv|giv[186]	coref	27-12
26-17	4031-4042	development	abstract[186]	giv[186]	_	_
26-18	4043-4044	.	_	_	_	_

#Text=In this study , to develop a new type of targeted drug delivery carrier material and investigate the anticancer mechanism of prodigiosin , we first used plCSA-BP as a guide peptide to coat on the DGL vector for cancer-cell-targeted delivery of prodigiosin produced from Serratia marcescens subsp . lawsoniana HDZK-BYSB107 .
27-1	4045-4047	In	_	_	_	_
27-2	4048-4052	this	abstract[187]	new[187]	_	_
27-3	4053-4058	study	abstract[187]	new[187]	_	_
27-4	4059-4060	,	_	_	_	_
27-5	4061-4063	to	_	_	_	_
27-6	4064-4071	develop	_	_	_	_
27-7	4072-4073	a	object[188]	new[188]	_	_
27-8	4074-4077	new	object[188]	new[188]	_	_
27-9	4078-4082	type	object[188]	new[188]	_	_
27-10	4083-4085	of	object[188]	new[188]	_	_
27-11	4086-4094	targeted	object[188]|substance[191]	new[188]|new[191]	_	_
27-12	4095-4099	drug	object[188]|substance|substance[191]	new[188]|giv|new[191]	_	_
27-13	4100-4108	delivery	object[188]|abstract|substance[191]	new[188]|giv|new[191]	_	_
27-14	4109-4116	carrier	object[188]|substance[191]	new[188]|new[191]	_	_
27-15	4117-4125	material	object[188]|substance[191]	new[188]|new[191]	_	_
27-16	4126-4129	and	_	_	_	_
27-17	4130-4141	investigate	_	_	_	_
27-18	4142-4145	the	abstract[192]	new[192]	coref	29-4[212_192]
27-19	4146-4156	anticancer	abstract[192]	new[192]	_	_
27-20	4157-4166	mechanism	abstract[192]	new[192]	_	_
27-21	4167-4169	of	abstract[192]	new[192]	_	_
27-22	4170-4181	prodigiosin	abstract[192]|substance	new[192]|giv	coref	27-42
27-23	4182-4183	,	_	_	_	_
27-24	4184-4186	we	person	acc	ana	28-3
27-25	4187-4192	first	_	_	_	_
27-26	4193-4197	used	_	_	_	_
27-27	4198-4206	plCSA-BP	abstract	giv	_	_
27-28	4207-4209	as	_	_	_	_
27-29	4210-4211	a	_	_	_	_
27-30	4212-4217	guide	_	_	_	_
27-31	4218-4225	peptide	_	_	_	_
27-32	4226-4228	to	_	_	_	_
27-33	4229-4233	coat	_	_	_	_
27-34	4234-4236	on	_	_	_	_
27-35	4237-4240	the	abstract[197]	giv[197]	coref	30-7[217_197]
27-36	4241-4244	DGL	abstract|abstract[197]	giv|giv[197]	_	_
27-37	4245-4251	vector	abstract[197]	giv[197]	_	_
27-38	4252-4255	for	_	_	_	_
27-39	4256-4276	cancer-cell-targeted	abstract[198]	new[198]	coref	30-14[0_198]
27-40	4277-4285	delivery	abstract[198]	new[198]	_	_
27-41	4286-4288	of	abstract[198]	new[198]	_	_
27-42	4289-4300	prodigiosin	abstract[198]|substance	new[198]|giv	_	_
27-43	4301-4309	produced	_	_	_	_
27-44	4310-4314	from	_	_	_	_
27-45	4315-4323	Serratia	_	_	_	_
27-46	4324-4334	marcescens	_	_	_	_
27-47	4335-4340	subsp	_	_	_	_
27-48	4341-4342	.	_	_	_	_
27-49	4343-4353	lawsoniana	time[200]	new[200]	_	_
27-50	4354-4366	HDZK-BYSB107	time[200]	new[200]	_	_
27-51	4367-4368	.	_	_	_	_

#Text=Then , we tested the binding ability of the newly developed DGL/CSA-PNPs and its anticancer effect in vitro on a JEG3 choriocarcinoma cell line and in vivo on a tumor model , respectively .
28-1	4369-4373	Then	_	_	_	_
28-2	4374-4375	,	_	_	_	_
28-3	4376-4378	we	person	giv	_	_
28-4	4379-4385	tested	_	_	_	_
28-5	4386-4389	the	abstract[202]	new[202]	_	_
28-6	4390-4397	binding	abstract[202]	new[202]	_	_
28-7	4398-4405	ability	abstract[202]	new[202]	_	_
28-8	4406-4408	of	abstract[202]	new[202]	_	_
28-9	4409-4412	the	abstract[202]|abstract[203]	new[202]|new[203]	_	_
28-10	4413-4418	newly	abstract[202]|abstract[203]	new[202]|new[203]	_	_
28-11	4419-4428	developed	abstract[202]|abstract[203]	new[202]|new[203]	_	_
28-12	4429-4441	DGL/CSA-PNPs	abstract[202]|abstract[203]	new[202]|new[203]	_	_
28-13	4442-4445	and	abstract[202]	new[202]	_	_
28-14	4446-4449	its	abstract[202]|abstract|abstract[205]	new[202]|giv|new[205]	coref	29-8[213_205]
28-15	4450-4460	anticancer	abstract[202]|abstract[205]	new[202]|new[205]	_	_
28-16	4461-4467	effect	abstract[202]|abstract[205]	new[202]|new[205]	_	_
28-17	4468-4470	in	abstract[202]|abstract[205]	new[202]|new[205]	_	_
28-18	4471-4476	vitro	abstract[202]|abstract[205]	new[202]|new[205]	_	_
28-19	4477-4479	on	abstract[202]|abstract[205]	new[202]|new[205]	_	_
28-20	4480-4481	a	abstract[202]|abstract[205]|object[209]	new[202]|new[205]|new[209]	_	_
28-21	4482-4486	JEG3	abstract[202]|abstract[205]|abstract|object[209]	new[202]|new[205]|new|new[209]	_	_
28-22	4487-4502	choriocarcinoma	abstract[202]|abstract[205]|abstract|object[209]	new[202]|new[205]|giv|new[209]	_	_
28-23	4503-4507	cell	abstract[202]|abstract[205]|object|object[209]	new[202]|new[205]|giv|new[209]	_	_
28-24	4508-4512	line	abstract[202]|abstract[205]|object[209]	new[202]|new[205]|new[209]	_	_
28-25	4513-4516	and	_	_	_	_
28-26	4517-4519	in	_	_	_	_
28-27	4520-4524	vivo	_	_	_	_
28-28	4525-4527	on	_	_	_	_
28-29	4528-4529	a	abstract[211]	new[211]	_	_
28-30	4530-4535	tumor	abstract|abstract[211]	giv|new[211]	_	_
28-31	4536-4541	model	abstract[211]	new[211]	_	_
28-32	4542-4543	,	_	_	_	_
28-33	4544-4556	respectively	_	_	_	_
28-34	4557-4558	.	_	_	_	_

#Text=In addition , the mechanism responsible for the anticancer effect of targeted nano-prodigiosin was also investigated .
29-1	4559-4561	In	_	_	_	_
29-2	4562-4570	addition	_	_	_	_
29-3	4571-4572	,	_	_	_	_
29-4	4573-4576	the	abstract[212]	giv[212]	_	_
29-5	4577-4586	mechanism	abstract[212]	giv[212]	_	_
29-6	4587-4598	responsible	abstract[212]	giv[212]	_	_
29-7	4599-4602	for	_	_	_	_
29-8	4603-4606	the	abstract[213]	giv[213]	_	_
29-9	4607-4617	anticancer	abstract[213]	giv[213]	_	_
29-10	4618-4624	effect	abstract[213]	giv[213]	_	_
29-11	4625-4627	of	abstract[213]	giv[213]	_	_
29-12	4628-4636	targeted	abstract[213]|object[214]	giv[213]|new[214]	_	_
29-13	4637-4653	nano-prodigiosin	abstract[213]|object[214]	giv[213]|new[214]	_	_
29-14	4654-4657	was	_	_	_	_
29-15	4658-4662	also	_	_	_	_
29-16	4663-4675	investigated	_	_	_	_
29-17	4676-4677	.	_	_	_	_

#Text=Overall , these findings suggested that the DGL/CSA vector is an excellent cancer-specific-drug delivery carrier , which has great potential as a novel delivery system for the treatment of cancer .
30-1	4678-4685	Overall	_	_	_	_
30-2	4686-4687	,	_	_	_	_
30-3	4688-4693	these	abstract[215]	new[215]	_	_
30-4	4694-4702	findings	abstract[215]	new[215]	_	_
30-5	4703-4712	suggested	_	_	_	_
30-6	4713-4717	that	_	_	_	_
30-7	4718-4721	the	organization[217]	giv[217]	coref	30-11[219_217]
30-8	4722-4729	DGL/CSA	organization|organization[217]	new|giv[217]	_	_
30-9	4730-4736	vector	organization[217]	giv[217]	_	_
30-10	4737-4739	is	_	_	_	_
30-11	4740-4742	an	organization[219]	giv[219]	_	_
30-12	4743-4752	excellent	organization[219]	giv[219]	_	_
30-13	4753-4773	cancer-specific-drug	organization[219]	giv[219]	_	_
30-14	4774-4782	delivery	abstract|organization[219]	giv|giv[219]	coref	30-24
30-15	4783-4790	carrier	organization[219]	giv[219]	_	_
30-16	4791-4792	,	_	_	_	_
30-17	4793-4798	which	_	_	_	_
30-18	4799-4802	has	_	_	_	_
30-19	4803-4808	great	abstract[220]	new[220]	_	_
30-20	4809-4818	potential	abstract[220]	new[220]	_	_
30-21	4819-4821	as	_	_	_	_
30-22	4822-4823	a	_	_	_	_
30-23	4824-4829	novel	_	_	_	_
30-24	4830-4838	delivery	abstract	giv	_	_
30-25	4839-4845	system	_	_	_	_
30-26	4846-4849	for	_	_	_	_
30-27	4850-4853	the	event[222]	new[222]	_	_
30-28	4854-4863	treatment	event[222]	new[222]	_	_
30-29	4864-4866	of	event[222]	new[222]	_	_
30-30	4867-4873	cancer	event[222]|abstract	new[222]|giv	_	_
30-31	4874-4875	.	_	_	_	_
